Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Rifaximin is in 2004 FDA-approved for the treatment of traveller’s diarrhea (TD) caused by non-invasive diarrheagenic Escherichia coli, but it is not approved by the EMA for TD. The indication specifically states treatment of traveller’s diarrhea excluding cases with bloody stools or fever, which may signal invasive pathogens such as Shigella, Salmonella, or Campylobacter. The recommended regimen is 200 mg three times daily for 3 days in adults.
Koo et al. 2009 Ther Clin…